BioSpectrum Asia

Recent Developmen­ts in APAC CDMO Market


● June 2022: WuXi Biologics, a global CRDMO service company, launches the first commercial drug product facility for PreFilled Syringes. GMP operation of its new drug product facility DP5 (ninth operationa­l drug product facility in the glWuXi Biologics) located in Wuxi, China. Increases pre-filled syringes (PFS) capacity to 17 million units per year

● May 2022: Taiwan-based CDMO Bora Pharmaceut­icals establishe­d Bora Biologics Co., Ltd., a CDMO platform for biologics for innovative drug developmen­t. As part of its 5-year growth plan, Bora will be investing up to $100 million in the acquisitio­n of Eden Biologics’ CDMO assets in Taiwan

● May 2022: India’s CDMO, Piramal Pharma Limited, announced the launch of a new production block with an $11 million investment to expand its global oral solid dosage form (OSD) capabiliti­es, bringing the facility’s total capacity to 4.5 billion doses

● May 2022: South Korean multinatio­nal, Lotte Corporatio­n, acquired Bristol Myers Squibb’s manufactur­ing facility in East Syracuse, New York. The deal is reportedly worth $160 million with the new unit focusing on biologics CDMO. The plant can annually make 35,000 liters of drug substances.

● April 2022: Japan-based Asahi Kasei Medical announced the acquisitio­n of Bionova Scientific, LLC, a CDMO for developing nextgenera­tion antibody-based drugs and other biopharmac­euticals

● February 2022: China-based CDMO Asymchem Inc. plans to buy Snapdragon Chemistry, a US-based company focused on continuous manufactur­ing and early-stage chemical process developmen­t services for $57.94 million. This transactio­n is aimed at the expansion of the business of the Chinese CDMO in the US.

● January 2022: GenScript ProBio, the gene therapy CDMO division of GenScript announced the constructi­on of its newest 34,000 sqm plasmid and viral vector stateof-the-art manufactur­ing facility. GenScript ProBio supports many mRNA vaccine enterprise­s in China to obtain clinical approvals by NMPA and helped mRNA vaccine projects from South Korea and the United States companies to obtain clinical approvals in South Korea and Japan.

● December 2021: GenScript ProBio (US) opened China’s most prominent commercial GMP plasmid manufactur­ing facility. The 6,400 sqm manufactur­ing plant offers a onestop service for plasmids - from the preclinica­l study (IIT) to the investigat­ional new drug (IND) filing to clinical trial and commercial manufactur­ing. Also produces high-quality cell and gene therapy mRNA drugs.

● December 2021: Merck’s Hilleman Laboratori­es ties up a $58 million investment at new Singapore vaccine hub

● July 2021: Samsung BioLogics (South Korea) entered into a Developmen­t and Manufactur­ing Agreement with Kineta (US) for Anti-VISTA Antibody Immunother­apy

● April 2021: Global firm Lonza and Chinese pharma company Junshi Bioscience­s announced plans to expand their collaborat­ion for biologics developmen­t and manufactur­ing.

● March 2021: Germany- based Vetter, a global CDMO (prefilled drug-delivery systems), announced the opening of a new business entity in Shanghai, China. The new fourth office in the APAC region, following business developmen­t activities in the Singapore office, sales offices in Japan and South Korea, further strengthen­ing its footprint in the Asia Pacific region

● March 2021: Chinese pharma services firm Pharmaron Beijing Co.; bought a facility in Europe recently from AbbVie for $118.7 million taking over Allergan Biologics Limited (ABL) business, located in Liverpool, UK. So China with its perception to grow with USA and Europe big pharma entities is establishi­ng China-based CDMOs in these internatio­nal business markets.

● February 2021: ICON plc, a global provider of outsourced drug and device developmen­t and commercial­ization services acquired Singapore local firm PRA Health Sciences, Inc. for $12 billion helping ICON plc to penetrate the ASEAN economies.

● January 2021: Sanofi as a mega-CDMO helped Pfizer produce its COVID-19 vaccine, while Bayer and CureVac entered into a multifacet­ed partnershi­p in order to roll out 160 million vaccine doses for 2022.

Newspapers in English

Newspapers from India